Emmaus Life Sciences, Inc. EMMA OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

15/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Emmaus Life Sciences, Inc. (EMMA) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 14/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

15/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — EMMA

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.05

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.12

Book Value / Share$0.00

Revenue / Share$0.19

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-55.54	$85.1K	$-5.94M	-6981.2%
2017	$-15.15	$128.5K	$-7.11M	-5535.3%
2018	$-11.16	$1.32M	$-9.6M	-729.4%
2019	$-1.30	$22.75M	$-54.84M	-241%
2020	$0.03	$23.17M	$1.35M	5.8%
2021	$-0.32	$20.61M	$-15.95M	-77.4%
2022	$-0.21	$18.39M	$-10.63M	-57.8%
2023	$-0.07	$29.6M	$-3.73M	-12.6%
2024	$-0.10	$16.65M	$-6.45M	-38.7%
2025	$-0.12	$12.45M	$-7.49M	-60.2%